Regulatory News:
Transgene SA (Paris:TNG) (Euronext: TNG) today announced its financial results as of September 30, 2014 (third quarter and first nine months of 2014).
During the first nine months of 2014, revenue from collaborative and licensing agreements was mainly composed of: (i) manufacturing and research and development services (0.9 million euros); and (ii) revenue from licensed technologies and products (0.6 million euros).
Help employers find you! Check out all the jobs and post your resume.
Transgene SA (Paris:TNG) (Euronext: TNG) today announced its financial results as of September 30, 2014 (third quarter and first nine months of 2014).
During the first nine months of 2014, revenue from collaborative and licensing agreements was mainly composed of: (i) manufacturing and research and development services (0.9 million euros); and (ii) revenue from licensed technologies and products (0.6 million euros).
Help employers find you! Check out all the jobs and post your resume.
